Izuchukwu F. Okpalanwaka

Izuchukwu F. Okpalanwaka

Auto-generated profile, based on publicly available information

Izuchukwu F. Okpalanwaka

Department of Immunotherapeutics and Biotechnology, Jerry H. Hodge School of Pharmacy, Texas Tech University Health Sciences Center, Abilene, Texas

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 April 2025 in Molecular Cancer Therapeutics
Verified
Journal Article
Closed access
IOIzuchukwu F. Okpalanwaka
Izuchukwu F. Okpalanwaka
Elizabeth DaugherityElizabeth Daugherity
Elizabeth Daugherity
AMAmanda L. McCormick
Amanda L. McCormick
TATrevor S. Anderson
Trevor S. Anderson
SSSavanna L. Smith
Savanna L. Smith
DLDevin B. Lowe
Devin B. Lowe
Colorectal cancer is a leading cause of cancer-related deaths worldwide. The current standard of care for patients may involve surgery, chemotherapy, and immune checkpoint inhibitors, but these approaches typically fail to secure durable responses against late-stage disease. Regorafenib (REG) is an FDA-approved tyrosine kinase inhibitor with immunomodulating properties for patients with colorectal cancer who progress on standard care, but 5-year relative survival rates for individuals dosed with the drug as a monotherapy are poor. We hypothesize that REG may be more appropriately leveraged alongside immunotherapeutic agents that specifically stimulate T-cell infiltration and activation within the tumor microenvironment (TME). We engineered a PD-L1/CD3 bispecific antibody (bsAb) that simultaneously binds PD-L1–expressing colorectal cancer cells and stimulates activated T cells in order to investigate combination strategies with REG in preclinical models of colorectal cancer. Combined REG + bsAb therapy safely initiated and sustained inhibition against MC38 and CT26 progression in vivo, and these effects correlated to improved CD8+ T-cell infiltration and activity within a type 1–prone TME. Additionally, cytotoxic CD8+ T cells from REG + bsAb–sensitized mice exhibited heightened tumor cell reactivity compared with animals treated with either agent alone. Therefore, the immunomodulatory benefits of REG can be effectively paired with a bsAb that anchors to colorectal cancer cells, diminishes immunosuppression (through PD-L1 blockade), and activates/sustains antigen-specific CD8+ T cells within the TME. Our newly described REG + bsAb regimen led to improved antitumor outcomes preclinically and may represent a promising future approach for patients with colorectal cancer.

1 August 2025
Verified
Other
Open access
IOIzuchukwu F. Okpalanwaka
Izuchukwu F. Okpalanwaka
Elizabeth DaugherityElizabeth Daugherity
Elizabeth Daugherity
AMAmanda L. McCormick
Amanda L. McCormick
TATrevor S. Anderson
Trevor S. Anderson
SSSavanna L. Smith
Savanna L. Smith
DLDevin B. Lowe
Devin B. Lowe
Supplementary Table 1 annotates sequences for the bsAb VH/VL.

1 August 2025
Verified
Other
Open access
IOIzuchukwu F. Okpalanwaka
Izuchukwu F. Okpalanwaka
Elizabeth DaugherityElizabeth Daugherity
Elizabeth Daugherity
AMAmanda L. McCormick
Amanda L. McCormick
TATrevor S. Anderson
Trevor S. Anderson
SSSavanna L. Smith
Savanna L. Smith
DLDevin B. Lowe
Devin B. Lowe
Supplementary Figure 9 confirms abscopal tumor effects after local REG/bsAb treatment.

1 August 2025
Verified
Other
Open access
IOIzuchukwu F. Okpalanwaka
Izuchukwu F. Okpalanwaka
Elizabeth DaugherityElizabeth Daugherity
Elizabeth Daugherity
AMAmanda L. McCormick
Amanda L. McCormick
TATrevor S. Anderson
Trevor S. Anderson
SSSavanna L. Smith
Savanna L. Smith
DLDevin B. Lowe
Devin B. Lowe
Supplementary Figure 8 provides a putative model for improved colon cancer protection after REG/bsAb sensitization

1 August 2025
Verified
Other
Open access
IOIzuchukwu F. Okpalanwaka
Izuchukwu F. Okpalanwaka
Elizabeth DaugherityElizabeth Daugherity
Elizabeth Daugherity
AMAmanda L. McCormick
Amanda L. McCormick
TATrevor S. Anderson
Trevor S. Anderson
SSSavanna L. Smith
Savanna L. Smith
DLDevin B. Lowe
Devin B. Lowe
Supplementary Figure 4 shows no observable adverse safety in animals after treatment with REG/bsAb.

1 August 2025
Verified
Other
Open access
IOIzuchukwu F. Okpalanwaka
Izuchukwu F. Okpalanwaka
Elizabeth DaugherityElizabeth Daugherity
Elizabeth Daugherity
AMAmanda L. McCormick
Amanda L. McCormick
TATrevor S. Anderson
Trevor S. Anderson
SSSavanna L. Smith
Savanna L. Smith
DLDevin B. Lowe
Devin B. Lowe
Supplementary Figure 2 details PD-L1 expression is not observably altered following REG exposure.